Clinical trials: Patients With Type 2 Diabetes
Dry Mouth, Xerostomia
"Hyaluronan" Formulation for Type 2 Diabetic Patients With Dry Mouth
An increased incidence of dental caries in association with poorly controlled diabetes has also been reported, Xerostomia (dry mouth) has been reported to be a common complaint of patients with diabetes, Without adequate saliva…
- Conditions
- Dry Mouth, Xerostomia, Type 2 Diabetics
- Trial name
- NCT03281486
- Testing
- HA formulation Oral Spray
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- You First Services
Diabetes, Diabetes Mellitus, Type 1
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
This study is conducted in Europe. The aim of the study is to gather information about hypoglycaemia (low blood glucose) among patients with Type 1 or Type 2 diabetes mellitus. The study is both retrospective and prospective.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01696266
- Testing
- No treatment given
- Where
- 24 sites in Argentina, Austria and 22 more
- Volunteers
- 29,304 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare India (NCT01351922)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- Novo Nordisk A/S
Latent Autoimmune Diabetes in Adult (LADA)
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).
- Trial name
- NCT00456027
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 17 sites in Sweden
- Volunteers
- 160 people
- Sponsor
- Diamyd Therapeutics AB
Diabetes Mellitus, Type 2
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)
The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.
- Trial name
- NCT00543361
- Testing
- MK0767, Comparator: metformin
- Volunteers
- 382 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242202
- Testing
- ipragliflozin, alpha glucosidase inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 113 people
- Sponsor
- Astellas Pharma Inc
Diabetes, Diabetes Mellitus, Type 2
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
- Trial name
- NCT03070704
- Testing
- insulin degludec/liraglutide
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in…
- Trial name
- NCT00996658
- Testing
- Linagliptin
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1
Prospective Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Trial name
- NCT04960514
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
- Trial name
- NCT00660907
- Testing
- dapagliflozin, glipizide, metformin hydrochloride
- Where
- 76 sites in Argentina, France and 8 more
- Volunteers
- 1,217 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Trial name
- SURPRISE (NCT01154244)
- Testing
- HOMA-IR
- Where
- 2 sites in South Korea
- Volunteers
- 1,439 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
- Trial name
- NCT00722371
- Testing
- Sitagliptin phosphate, Pioglitazone hydrochloride, Metformin
- Volunteers
- 1,615 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin
The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch.
- Trial name
- SWING (NCT00549887)
- Testing
- Analog or Human Insulin
- Where
- 27 sites in Austria, Czechia and 7 more
- Volunteers
- 2,459 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.
- Trial name
- START (NCT00687284)
- Testing
- insulin detemir
- Where
- Slovakia
- Volunteers
- 2,188 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
- Trial name
- AWARD-10 (NCT02597049)
- Testing
- Dulaglutide, SGLT2 inhibitor, Metformin
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Hypertriglycemia
Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia
Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in subjects with type 2 Diabetes combined with hyperlipidemia
- Trial name
- NCT02305355
- Testing
- Omega-3-acids ethylesters 90 4g, Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
T2DM (Type 2 Diabetes Mellitus)
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with…
- Trial name
- NCT07580638
- Testing
- SGLT-2 inhibitor and Chiglitazar, SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs)
- Volunteers
- 3,550 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Type II Diabetes Mellitus
Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.
- Trial name
- ADME (NCT00960791)
- Testing
- AZD1656
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based…
- Trial name
- NCT00437489
- Testing
- Inhaled Human Insulin (Exubera)
- Where
- 9 sites in Hong Kong, Pakistan and 2 more
- Volunteers
- 49 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.